Conviction: Medium
Status: Researching
Quick Snapshot
| Signal |
Reading |
| Overall |
🟢 EXTREME OVERSOLD - RSI 9, -19.7% 30D, surgical robotics monopoly at deep discount |
| Moat |
Wide |
| Key insight |
RSI 8-9 for 10+ consecutive days. This NEVER happens for quality monopolies. da Vinci 5 FDA expansion bullish. |
Action Matrix
| Action |
Level |
Why |
| Current |
✅ Buy |
RSI 9 = extreme oversold, wide moat monopoly at 30D low |
| Entry Zone |
$460 - $500 |
Current price deep in zone |
| Stop-Loss |
$425 (-10.8%) |
52-week low support |
| Target |
$600 (+26%) |
Return to 30D ago levels / 52-week high area |
Price Data
| Stock |
Price |
1D |
7D |
30D |
3M |
52wkHi |
RSI |
Status |
Action |
| ISRG |
$476.32 |
-0.5% |
-9.4% |
-19.7% |
-13.0% |
-21.8% |
9↓ |
🟢 EXTREME OVERSOLD |
✅ Buy |
Legend
- RSI
↓ = Oversold (<30) - potential buying opportunity
- RSI
↑ = Overbought (>70) - FOMO warning, may pullback
- 52wkHi = % from 52-week high (how far below peak)
Price History (30D)
| Date |
Close |
RSI |
Note |
| 01/06 |
$592.85 |
-- |
30D start |
| 01/14 |
$546.76 |
-- |
First big drop |
| 01/20 |
$527.44 |
-- |
Continued decline |
| 01/26 |
$528.81 |
10 |
RSI enters extreme |
| 01/27 |
$525.04 |
10 |
Holding extreme |
| 01/28 |
$522.04 |
9 |
Further decline |
| 01/29 |
$507.55 |
9 |
Acceleration lower |
| 01/30 |
$504.22 |
7 |
RSI hits 7 (!!) |
| 02/02 |
$496.73 |
8 |
Below $500 |
| 02/03 |
$478.88 |
7 |
New low, RSI 7 |
| 02/04 |
$478.49 |
8 |
Stabilizing? |
| 02/05 |
$476.32 |
9 |
Still grinding lower |
Pattern: 10 consecutive days of RSI below 11. This is historically extreme for any large-cap quality stock.
Company Overview
One-Liner
Intuitive Surgical develops and manufactures the da Vinci robotic surgical system, enabling minimally invasive surgery worldwide.
Business Model
| Question |
Answer |
| What they sell |
da Vinci surgical robots, Ion endoluminal system, instruments, accessories, services |
| Who pays |
Hospitals, surgical centers, healthcare systems globally |
| Revenue model |
Capital sales (robots) + recurring (instruments/accessories per procedure + service contracts) |
| How sticky |
Extremely sticky - surgeons train on da Vinci, hospitals invest $1-2M per system, high switching costs |
Key Segments
| Segment |
Revenue % |
Growth |
Notes |
| Instruments & Accessories |
~57% |
+15-18% |
Recurring per-procedure revenue |
| Systems |
~27% |
Variable |
Capital equipment sales |
| Services |
~16% |
+10-12% |
Maintenance, training, support |
Geographic Mix
| Region |
Revenue % |
Notes |
| US |
~67% |
Mature market, procedure growth |
| International |
~33% |
High growth, underpenetrated |
Competitive Analysis
Industry Position
| Question |
Answer |
| Market share |
~80% global surgical robotics |
| Market size (TAM) |
~$20 billion (growing to $75B by 2030) |
| Growth rate |
~15% CAGR |
| Key competitors |
Medtronic (Hugo), J&J (Ottava), Stryker, Asensus |
| Position |
Dominant Leader |
Competitive Moat
| Moat Type |
Present? |
Evidence |
| Network effects |
🟢 |
Surgeon training ecosystem - surgeons learn on da Vinci, prefer it |
| Switching costs |
🟢 |
$1-2M per system, surgeon retraining, hospital workflow integration |
| Cost advantages |
🟢 |
Scale economics - 9,000+ installed base drives instrument volume |
| Intangible assets |
🟢 |
4,600+ patents, FDA clearances, brand trust with surgeons |
| Efficient scale |
🟢 |
Dominant position in niche market, competitors struggle to gain share |
Moat Assessment
Moat Width: Wide
Moat Trend: Widening (da Vinci 5 + Ion expanding into new procedures)
Summary:
Intuitive Surgical has one of the widest moats in healthcare technology. The combination of 80% market share, thousands of trained surgeons, massive installed base, 4,600+ patents, and FDA clearance portfolio creates near-insurmountable barriers. The da Vinci 5 system and Ion expansion into lung biopsy/cardiac procedures are actively widening the moat.
Management Assessment
Leadership
| Role |
Name |
Since |
Background |
Notes |
| CEO |
Gary Guthart, PhD |
2010 |
PhD robotics, 28+ years at Intuitive |
Founder-era leadership |
| CFO |
Jamie Samath |
2018 |
Former Seagate, Cypress Semi |
Financial discipline |
| Key Exec |
Bob DeSantis |
2020 |
Chief Business Officer |
Growth strategy |
Founder Involvement
| Question |
Answer |
| Founder-led? |
No (founder retired but founder-era CEO) |
| Founder ownership |
Minimal (Frederic Moll founded 1995) |
| Skin in the game |
Management has significant equity compensation |
Capital Allocation
| Metric |
Track Record |
| M&A discipline |
Good - selective, focused acquisitions |
| Buyback timing |
Good - consistent repurchase program |
| R&D investment |
High - ~15% of revenue, da Vinci 5, Ion |
| Debt management |
Conservative - net cash position |
Red Flags
- Excessive insider selling: -$313.9M net (significant caution signal)
- High turnover in key roles
- Related party transactions
- Aggressive accounting
Insider Selling Note: -$313.9M in net insider selling is a significant red flag. This could be routine diversification at elevated prices (stock was at $600+), but the magnitude warrants monitoring. Insiders may have been selling into strength before the correction.
Financials
Key Metrics
| Metric |
Current |
1Y Ago |
3Y Ago |
Trend |
| Revenue |
~$8.3B |
~$7.1B |
~$5.7B |
📈 |
| Revenue Growth YoY |
~17% |
~14% |
~12% |
📈 |
| Gross Margin |
~67% |
~66% |
~65% |
📈 |
| Operating Margin |
~30% |
~28% |
~25% |
📈 |
| FCF Margin |
~25% |
~24% |
~22% |
📈 |
| Net Debt/EBITDA |
Net cash |
Net cash |
Net cash |
📈 |
Quality Checks
| Check |
Status |
Notes |
| FCF positive? |
🟢 |
Consistently strong FCF generation |
| Profitable? |
🟢 |
Highly profitable, expanding margins |
| Debt manageable? |
🟢 |
Net cash position, no debt concerns |
| Cash runway |
Infinite |
Self-funding with strong cash flow |
Revenue Quality
| Factor |
Assessment |
| Recurring % |
~73% (instruments + services) |
| Customer concentration |
Low - thousands of hospitals worldwide |
| Contract length |
Multi-year service contracts |
| NRR/NDR |
High - hospitals add systems, increase procedures |
Leading Indicators
| Indicator |
Value |
Signal |
| Revenue Acceleration |
+17% YoY |
🟢 Accelerating |
| YoY Growth |
+17% |
🟢 Strong |
| Earnings Beat Rate |
>80% |
🟢 Consistent beats |
| Insider Trading |
-$313.9M net |
🔴 Heavy selling |
| Composite |
Mixed |
🟡 Fundamentals strong, insiders concerning |
Valuation
Current Multiples
| Metric |
Current |
5Y Avg |
Industry Avg |
| P/E |
~55x |
~65x |
~25x |
| P/S |
~20x |
~25x |
~5x |
| EV/EBITDA |
~45x |
~50x |
~18x |
| P/FCF |
~60x |
~70x |
~30x |
Historical Range
| Metric |
Current |
5Y High |
5Y Low |
% of Range |
| P/S |
~20x |
~30x |
~15x |
33% |
| EV/EBITDA |
~45x |
~60x |
~35x |
40% |
Fair Value Estimate
| Method |
Fair Value |
Upside/Downside |
| Historical avg P/S |
$570 |
+19.7% |
| DCF (15% growth, 25x terminal) |
$550 |
+15.5% |
| Comps (premium to MedTech) |
$520 |
+9.2% |
My Fair Value: $550 (based on historical average and DCF blend)
Bull Case
Why This Could Work (4 Reasons)
RSI 9 = Historically Extreme Oversold
- Evidence: 10+ consecutive days of RSI below 11
- Implication: Mean reversion likely, this level rarely persists for quality names
da Vinci 5 + Cardiac FDA Expansion
- Evidence: FDA clearance for cardiac procedures (Feb 2026 news)
- Implication: TAM expansion into $10B+ cardiac surgery market
80% Market Share Monopoly
- Evidence: 9,000+ installed systems, 4,600+ patents
- Implication: Competitors (Medtronic Hugo, J&J Ottava) years behind
73% Recurring Revenue
- Evidence: Instruments + services = predictable revenue stream
- Implication: Each installed system generates 10+ years of high-margin consumable revenue
Upside Scenario
| If This Happens |
Stock Could |
| RSI mean reversion to 50 |
$550-570 (+15-20%) |
| da Vinci 5 cardiac adoption accelerates |
$600+ (+26%) |
| International expansion inflects |
$650+ (+36%) |
Bear Case
What Could Go Wrong (4 Risks)
Massive Insider Selling (-$313.9M)
- How it plays out: Insiders know something about growth deceleration or competitive threats
- Probability: Medium
Competition Finally Arrives
- How it plays out: Medtronic Hugo or J&J Ottava gain meaningful share
- Probability: Low (2-3 year timeline before real threat)
Valuation Still Rich
- How it plays out: Even at 20x P/S, ISRG trades at massive premium to MedTech peers
- Probability: Medium - multiple compression could continue
Healthcare Spending Slowdown
- How it plays out: Hospitals delay capital purchases, procedure volumes decline
- Probability: Low-Medium
Thesis Killers
- Competitor surgical robot achieves clinical equivalence AND lower cost
- Major safety/recall event with da Vinci system
- Sustained insider selling acceleration beyond -$313.9M
Downside Scenario
| If This Happens |
Stock Could |
| Multiple compression to 15x P/S |
$400 (-16%) |
| Competitive threat materializes |
$380 (-20%) |
| 52-week low retest |
$425 (-10.8%) |
Market-Moving News
Recent News
| Date |
Headline |
Source |
Impact |
Relevance |
| 2026-02-06 |
ISRG facing share price challenges, -8% weekly, -19% yearly |
Yahoo Finance |
🔴 |
Price decline acknowledgment |
| 2026-02-03 |
FDA clearance for da Vinci 5 cardiac procedures |
Yahoo Finance |
🟢 |
TAM expansion catalyst |
| 2026-01-20 |
"Easy buy and hold for long-term outperformance" - 80% market share |
StockAnalysis |
🟢 |
Fundamental strength confirmed |
| 2026-01-15 |
"Is the smart money moving in?" - high margins, cash generation |
MarketBeat |
🟢 |
Institutional interest |
News Patterns
ISRG typically moves on: FDA clearances (bullish), quarterly procedure volume reports (bullish if growing), competitive robot announcements (bearish knee-jerk, usually recovers), and insider trading disclosures. The market overreacts to short-term competitive fears and underappreciates the installed base moat.
| Symbol |
Name |
Relationship |
30D |
Status |
Notes |
| XLV |
Healthcare SPDR |
Sector ETF |
~-2% |
🟡 |
Healthcare broadly flat |
| IHI |
iShares Med Devices |
Contains ISRG |
~-5% |
🔴 |
MedTech under pressure |
| ROBO |
Robo Global Robotics |
Robotics ETF |
~-3% |
🟡 |
Robotics broadly down |
Sector Context
ISRG is underperforming its sector significantly (-19.7% vs healthcare -2%). This is company-specific selling pressure, not a broad sector rotation. The disconnect between ISRG's fundamentals (accelerating revenue, expanding margins) and price action (RSI 9) suggests capitulation selling.
Cross-References (Where This Appears in Our System)
| Location |
File |
Context |
| Deep Dives |
deep-dives/2026-02-05-ISRG.md |
This file |
| Candidates |
candidates/ |
Not currently in any theme |
| Watchlists |
watchlists/ |
Should be added to healthcare watchlist |
| Ticker |
Why Related |
Suggested Placement |
Priority |
Notes |
| MDT |
Competitor (Hugo robot) |
watchlists/healthcare |
🟡 |
Monitor competitive progress |
| JNJ |
Competitor (Ottava) |
watchlists/healthcare |
🟡 |
Watch for Ottava timeline |
| SYK |
Competitor (Mako) |
watchlists/healthcare |
🟡 |
Orthopedic robotics |
| DHR |
Life sciences / diagnostics |
Already tracked |
🟡 |
Peer comparison |
Catalysts & Timing
Upcoming Catalysts
| Date |
Event |
Impact |
Watch For |
| 2026-Q1 |
Q4 2025 Earnings |
🟢 |
Procedure volume growth, da Vinci 5 placements |
| 2026 H1 |
da Vinci 5 cardiac procedure ramp |
🟢 |
Adoption rate, surgeon feedback |
| Ongoing |
International expansion updates |
🟢 |
China/Japan market penetration |
| Ongoing |
Insider trading disclosures |
🔴 |
Any acceleration of selling |
Key Dates
| Event |
Frequency |
Next Date |
| Earnings |
Quarterly |
~April 2026 (Q4 2025) |
| Investor Day |
Annual |
TBD |
| FDA submissions |
Irregular |
Watch for Ion expansion |
Entry Strategy
Position Sizing
| Conviction |
Allocation |
| Speculative |
0% (research only) |
| Low |
1-2% |
| Medium |
3-5% |
| High |
5-10% |
My conviction: Medium
Target allocation: 3-5%
Entry Approach
| Strategy |
Details |
| Entry zone |
$460 - $500 (current range) |
| Starter position |
50% of target (1.5-2.5%) |
| Add on |
RSI stays <15 for another week OR bounces above RSI 30 |
| Full position at |
Confirmed RSI mean reversion above 30 + earnings beat |
Technical Levels
| Level |
Price |
Notes |
| Support 1 |
$475 |
Current area, psychological level |
| Support 2 |
$462 |
BB lower band |
| Support 3 |
$425 |
52-week low |
| Resistance 1 |
$527 |
SMA 20 (overhead) |
| Resistance 2 |
$550 |
Fair value estimate |
| 52-week high |
$609.08 |
|
| 52-week low |
$425.00 |
|
Research Checklist
Fundamentals
- Review revenue drivers (instruments/accessories recurring model)
- Understand business model and moat
- Read most recent 10-K/10-Q
- Listen to last 2 earnings calls
- Review investor presentations
Competitive
- Map competitive landscape (Medtronic Hugo, J&J Ottava, Stryker)
- Assess moat durability (Wide, widening)
- Check customer reviews/NPS
Management
- Research CEO background (Gary Guthart, 28+ years)
- Check insider ownership (-$313.9M net selling = red flag)
- Review capital allocation history in detail
Valuation
- Review historical multiples (trading at lower end of 5Y range)
- Compare to peers (premium justified by moat)
- Identify entry/exit zones ($460-500 entry, $550+ target)
Risk
- Write bear case (4 risks identified)
- Identify thesis-killers (competitive equivalence, safety event)
- Set stop-loss level ($425)
Sources
| Type |
Link |
Notes |
| Company Website |
https://www.intuitive.com |
Investor relations |
| SEC Filings |
SEC EDGAR |
10-K, 10-Q, insider filings |
| News |
Yahoo Finance, MarketBeat, StockAnalysis |
Recent coverage |
Research Log
| Date |
Update |
| 2026-02-05 |
Created deep dive. RSI 9, extreme oversold. da Vinci 5 cardiac FDA clearance. Insider selling -$313.9M is concerning. |
The Gold
Key Discoveries
| Discovery |
Implication |
| RSI 9 for 10+ consecutive days |
Historically extreme - mean reversion likely |
| da Vinci 5 FDA cardiac clearance |
TAM expansion into $10B+ market |
| 80% global surgical robotics market share |
Near-monopoly with 4,600+ patents |
| 73% recurring revenue |
Installed base generates predictable cash flow |
| -$313.9M insider selling |
Major caution signal - may know something |
| Market cap $169B at $476 |
Premium valuation even after -20% drop |
Open Questions
- Why are insiders selling so aggressively? Routine diversification or knowledge-based?
- When does the da Vinci 5 cardiac procedure volume ramp materially?
- Is the RSI 9 driven by sector rotation or ISRG-specific factors?
- What's the Q4 2025 earnings estimate and procedure volume guidance?
- How is Medtronic Hugo performing in competitive evaluations?
Mistakes (If Applicable)
| Mistake |
Lesson |
| N/A - first look |
Need to monitor insider selling trajectory closely |